Redeye initiates coverage of OssDsign, a medtech company offering patient-specific bioceramic cranial implants with significantly lower risk of implant removal due to infection compared to established treatment. With US market presence since 2017, strong clinical validation, and reimbursements in place, we see significant sales growth potential ahead. At current share price levels, we see an attractive entry to this momentum story and include it in Redeye's Conviction Buy List.